Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Regenxbio (RGNX) Leases (2019 - 2025)

Regenxbio has reported Leases over the past 7 years, most recently at $47.2 million for Q4 2025.

  • Quarterly results put Leases at $47.2 million for Q4 2025, down 12.21% from a year ago — trailing twelve months through Dec 2025 was $47.2 million (down 12.21% YoY), and the annual figure for FY2025 was $47.2 million, down 12.21%.
  • Leases for Q4 2025 was $47.2 million at Regenxbio, down from $48.8 million in the prior quarter.
  • Over the last five years, Leases for RGNX hit a ceiling of $65.1 million in Q4 2022 and a floor of $47.2 million in Q4 2025.
  • Median Leases over the past 5 years was $60.0 million (2022), compared with a mean of $58.1 million.
  • Biggest five-year swings in Leases: soared 621.25% in 2021 and later decreased 12.21% in 2025.
  • Regenxbio's Leases stood at $60.9 million in 2021, then grew by 6.92% to $65.1 million in 2022, then decreased by 7.11% to $60.5 million in 2023, then fell by 11.19% to $53.7 million in 2024, then decreased by 12.21% to $47.2 million in 2025.
  • The last three reported values for Leases were $47.2 million (Q4 2025), $48.8 million (Q3 2025), and $50.5 million (Q2 2025) per Business Quant data.